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Background: Leptin, the cytokine produced by white adipose tissue is known to regulate food energy homeostasis
through its hypothalamic receptor. In vitro studies have demonstrated that leptin plays a major role in angiogenesis
through binding to the receptor Ob-R present on ECs by stimulating and initiating new capillary like structures from
ECs. Various in vivo studies indicate that leptin has diverse effect on angiogenesis. A few reports have showed that
leptin exerts pro angiogenic effects while some suggested that it has antiangiogenic potential. It is theoretically
highly important to understand the effect of leptin on angiogenesis to use as a therapeutic molecule in various
angiogenesis related pathological conditions. Chicken chorio allantoic membrane (CAM) on 9th day of incubation
was incubated with 1, 3 and 5 μg concentration of HRL for 72 h using gelatin sponge. Images where taken after
every 24 h of incubation and analysed with Angioguant software. The treated area was observed under microscope
and histological evaluation was performed for the same. Tissue thickness was calculated morphometrically from
haematoxylin and eosin stained cross sections. Reverse transcriptase PCR and immunohistochemistry were also
performed to study the gene and protein level expression of angiogenic molecules.
Results: HRL has the ability to induce new vessel formation at the treated area and growth of the newly formed
vessels and cellular morphological changes occur in a dose dependent manner. Increase in the tissue thickness at
the treated area is suggestive of initiation of new capillary like structures. Elevated mRNA and protein level
expression of VEGF165 and MMP2 along with the activation of ECs as demonstrated by the presence of CD34
expression supports the neovascularization potential of HRL.
Conclusion: Angiogenic potential of HRL depends on the concentration and time of incubation and is involved
in the activation of ECs along with the major interaction of VEGF 165 and MMP2. It is also observed that 3 μg of
HRL exhibits maximum angiogenic potential at 72 h of incubation. Thus our data suggest that dose dependent
angiogenic potential HRL could provide a novel role in angiogenic dependent therapeutics such as ischemia and
wound healing conditions.
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The Ob-gene product leptin is 16 kDa peptide hormone,
produced mainly by white adipose tissue is proposed to
play a key role in the regulation of body weight and
thermogenesis through the receptor found in the hypo-
thalamus [1]. Accumulating evidences from in vitro and
in vivo assays suggest that leptin promote endothelial
cell (EC) proliferation and survival in favour of angio-
genesis [2, 3]. In vivo and in vitro results from Hyung
et al. study indicates that angiogenic potential of leptin
is mediated by matrix metalloproteinase (MMPs) [4].
However, the actual mechanism behind the involvement
of matrix metalloproteinase in leptin mediated angiogen-
esis is not clear.
The effect of leptin on angiogenesis is still not under-
stood as some reports have suggested its potential to in-
duce angiogenesis while some have indicated of its anti
angiogenic effect [5–9]. Recently it has been reported
that in ovo administration of leptin inhibited angiogen-
esis on chicken chorio allantoic membrane (CAM) [10].
Leptin has been administered as a therapeutic molecule
in various angiogenesis related pathological conditions
especially in wound healing [11]. However a quantitative
in vivo evaluation on the effect of leptin on angiogenesis
is important because of its therapeutic application po-
tential in the pathology of angiogenesis dependent con-
ditions. Therefore in the present study we examined the
angiogenic potential of human recombinant leptin (HRL)
using well vascularized CAM of developing chicken em-
bryo (Gallus gallus domesticus). The advantage of CAM
assay is that it is a highly vascularized structure with po-
tential growth and this in ovo vivo system is highly useful
to understand the physiological angiogenesis and hence
widely used for the screening of various compounds for
their angiogenic activity [12].
In the present study we analysed and compared the
angiogenic ability of HRL of varying concentrations such
as 1, 3 and 5 μg for an incubation period of 72 h using late
CAM. Gelatin sponges soaked with leptin were placed on
the membrane at 9th day of post incubation so as to allow
slow delivery of the chemical at the treated area with less
or no inflammation [13, 14]. The ability of HRL to induce
new vessel growth at the treated area is directly visualized
from the CAM images taken at different time period of in-
cubation and growth of these vessels measured with Image
J and Angioquant MATLAB softwares [14–16]. Angio-
genic response of HRL at the treated area is further ana-
lysed in detail from the histological sections. We also
examined the expression of major angiogenic molecules at
the molecular and protein level to understand the involve-
ment of these factors on HRL induced angiogenesis. Our
findings suggest that the potential of HRL to induce
angiogenesis depends on various physiological factors
especially dose and time of incubation. The result havedemonstrated that HRL favours neovascularization
through sprouting of vessels which is accelerated by the
expression of VEGF165 and MMP2 in a dose dependent
way in chicken CAM vasculature.
Methods
Materials
Fertilized white leghorn chicken eggs were purchased
from Tamil Nadu Poultry Research Station, Madras Vet-
erinary University, Nandanam, Tamil Nadu, India. Gel-
atin sponges purchased from Jhonson & Jhonson Pvt
Lmtd, India, Paraffin film and wax were purchased from
Sigma, Aldrich, USA. Haematoxylin and Eosin stain pur-
chased from Medox, India and Human recombinant lep-
tin from MP Biomedicals, Inc. France. TRIzol reagent,
agarose and EtBr were from Sigma, Aldrich, USA.
ImProm-11™ Reverse Transcriptase kit and GoTaq Green
Master Mix PCR amplification kit were from Promega,
USA, Oligo (dt) of length 18-meres from eurofins, mwg
operon, Germany, Random hexamers from MP Biomedi-
cals, USA. All primers were purchased from Bioserve,
India. DNA ladders purchased from Invitrogen, USA.
DAB system purchased from Bangalore Genei, India.
CD34 antibody (Endothelial Cell Marker, Cluster desig-
nation 34) from US Biological, USA and VEGF A from
CALBIOCHEM, EMD. Bradford reagent and FITC (Goat
ant-rabbit IgG were from Bangalore Genei, India. SDS-
PAGE Standards marker was from BIO-RAD, CANADA
and gelatin from Medox, India. Rabbit polyclonal MMP2
is a kind gift from Dr. Li Haiqing, MD, Ph.D, −Technology
transfer specialist, National Cancer Institute, Rockville,
USA. Unless otherwise specified all other common re-
agents and chemicals were purchased from Sigma,
Aldrich, USA.
The in ovo CAM model
Fertilized white leghorn chicken eggs weighing 50 ± 2 g,
were incubated at 37 °C in a ‘humidified atmosphere
(>60 % relative humidity) as per the protocol described
in Hen’s Egg Test - Chorioallantoic Membrane (HET-
CAM) method adapted from ZEBET (The German
Centre for the Documentation and validation of Alterna-
tive Methods, Republic of Germany). At day 3 of post
incubation, 2 to 3 ml of albumin was withdrawn, using a
21 gauge needle, through the large blunt edge of the egg
in order to minimize the adhesion of the shell membrane
with CAM. A square window of 2 cm2 was opened in the
egg shell and sealed with paraffin film to prevent
dehydration and the eggs were incubated further. At day 9
of post incubation, gelatin sponges of size of 1 mm3 were
placed on top of the growing CAM under sterile condition
[14, 17] and were soaked with 15 μl volume of 1, 3 and
5 μg concentration of HRL. Control eggs were incubated
with 1X PBS (pH-7.3). The window was closed with a
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72 h until it reached post incubation day 12. CAM were
photographed at 0, 24, 48 and 72 h using Canon digital
camera and images were analysed with Image J and Angio-
quant Toolbox, MATLAB 6.5 software to measure total
length and size of the blood vessels (micrometre) from the
area of treatment.
Light microscope analysis
After 72 h of incubation the area of the CAM treated with
HRL was detached carefully. The excised membrane was
kept on glass slides and images were taken using light
microscope both at 4 and 10× magnification to view the
growth of capillaries [18].
Histology
After 72 h of incubation area of the CAM treated with
HRL was flooded with Bouin’s fixative solution. Around
1 cm2 of the membrane around the treated area was re-
moved carefully using forceps and surgical scissors and
dehydrated through graded series of alcohol (50 %, 70 %,
90 % and absolute) and embedded in paraffin wax. Verti-
cal cross tissue sections (7 μm in thickness) were taken
using Rotary Microtome (Weswicox, Japan). Sections were
treated with alcohol in ascending order (absolute, 90 %,
70 %, and 50 %) and cleared with xylene before staining
with haematoxylin and eosin. After mounting with DPX,
the histological sections were observed under light micro-
scope at 40× magnification for qualitative assessment and
images were recorded using Nikon Camera attached with
light microscope at 10× magnification [14].
Morphometric analysis of CAM tissue thickness (DCAM)
Thickness of the CAM for all the groups treated with
HRL were measured from haematoxylin and eosin
stained vertical cross sections using a calibrated object-
ive at 40× magnification with 10 × 10 calibrated grid at
10× ocular. Distances between the chorionic and allan-
toic epithelial layers were measured in micrometre at 6
different locations from the same sample and is repeated
for six serial cross sections of the same. Average tissue
thickness was calculated from each tissue sample of the
same and obtained a mean DCAM thickness [14, 19].
Semi-Quantitative Reverse Transcriptase–Polymerase
Chain Reaction (RT-PCR)
Total RNA was isolated from CAM treated with HRL
using TRIzol reagent (100 mg/1 ml). The quantity and
the purity of the isolated RNA were checked using UV-
visible spectrophotometer. cDNA of 20 μl volume was
synthesized using ImProm-11™ Reverse Transcriptase kit
with Oligo (dt) of length 18-meres and random hexam-
ers. PCR amplification was performed using GoTaq
Green Master Mix kit and changes in the level of mRNAexpression of VEGF165 [20], VEGF121 [21], MMP2 [20],
MMP9 [22] and GAPDH [23] were evaluated using PCR
with 100 pico moles of specific primers. The relative ex-
pression level of each mRNA transcript was normalized
with that of control. PCR products were subjected to
electrophoresis.
Gelatin zymography
CAM tissues at the treated area from each group were
homogenized (100 mg/ml) using Tris buffer (0.5 M
Tris–HCl (pH-6.8), 10 % SDS, glycerol and 0.01 %
bromophenol blue) and centrifuged at 12,000 rpm/4 °C/
10 min. The concentration of protein from the super-
natant was determined using Bradford reagent and the
gelatinase activity was examined on a 10 % SDS-PAGE
electrophoresis containing 1.0 mg/ml of gelatin. Protein
samples of 25 μg/40 μl were loaded per well along with
20 μl pertained SDS-PAGE Standards marker. After
electrophoresis, the gels were washed with 2.5 % of
Triton-X-100 and incubated in digestion buffer (50 mM
Tris HCl-pH-7.5,100 mM CaCl2, 1 μM ZnCl2, 1 % Tri-
ton X-100, 0.02 % NaN3-100 ml) for 16 to 18 h at 37 °C
with gentle agitation. The gel was stained with staining
solution (0.05 % (w/v, Coomassie blue in 50 % methanol
and 10 % acetic acid) for 1 h and de stained with metha-
nol/acetic acid mixture. Gelatinase activity of MMP2
was detected as clear white bands against background.
The gels were scanned and images were recorded using
BIO-RAD Calibrated Densitometer Software (GS 800,
USA). The density of the bands was calculated with PD
Quest Advances Software and normalized with control
value [24].
Immunohistochemistry
Three different concentration namely 1, 3 and 5 μg of
HRL have been used of which 3 μg of HRL yielded max-
imum angiogenic response when compared to other two
concentrations. The deparafinized and dehydrated CAM
of 5 μM thickness after treating with 3 μg of HRL was
allowed to undergo antigen retrieval process using So-
dium Citrate (10 mM-pH 6.0) in a microwave oven for
20 min followed by washing in DDH2O for 3X5 min in
1X PBS (pH 7.3). Normal Goat Serum Blocking Solution
(2 % goat serum,1 % BSA, 0.1 % cold fish skin gelatin,
0.1 % Triton X-100, 0.05 % Tween- 20, 0.05 % Sodium
Azide, 0.01 M PBS (pH 7.2) of 50 to 75 μl was added im-
mediately on the sections and incubated for 1 h in a hu-
midified chamber. After washing with 1X PBS, primary
antibodies of MMP2 (1:200), VEGF (VEGF A) (1:100)
and CD34 (1:200) diluted in blocking serum were ap-
plied on the sections and after overnight incubation
rinsed with 1X PBS with 0.05 % of Tween-20. Diluted
FITC (Goat ant-rabbit IgG) and HRP (both Goat anti-
rabbit and Goat anti- mouse IgG) secondary antibodies
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turer’s instruction. For HRP conjugated secondary anti-
bodies DAB system was used for colour development. The
slides were finally counterstained with Mayer’s haema-
toxylin and mounted with 90 % of glycerol. For HRP con-
jugated system the images were recorded using light
microscope and for FITC conjugation BX51 Olympus
Fluorescence Microscope at a wavelength of 515 nm with
ASI FISH View 5.5 software at 40× magnification [25].
Data analysis and statistical analysis
All experiments were independently performed in tripli-
cate. Data were analysed using one way ANOVA analysis
of variance test and Tukey post hoc test as appropriate
(Sigma stat 2.0). Data were expressed as means + S.E.M
and P-values of *p = < 0.001 and #p = 0.001 were selected
for showing statistically significant difference.Fig. 1 Human recombinant leptin initiate new blood vessel formation and ac
concentration of HRL and control with 1X PBS for 72 hours. Figure panel repr
blood vessels formation around the sponge as spoke wheel pattern was obse
CAM when compared to control (b) at 72 hours of incubation. Figure a, c, e a
HRL respectively. Images are taken using Cannon digital camera at 4X magnif
experiments. Arrow indicates the presence of new blood vessels. b Images of
with Image J and Angioquant software to measure total vessel length (graph
HRL shows significant increase in the length and size of the blood vessels at 4
significant increase in the vessel length and size. Though both the concentrat
comparatively higher than that of 5 μg of HRL. Value at 0 h was taken as one
SEM, (*p = <0.001 and #p = 0.001 versus control)Results
Human recombinant leptin induces neo vascularization -
visual assessment of new blood vessel formation on CAM
vascular bed and its growth
The main focus of the present study is to visualize directly
the angiogenic ability of HRL to induce new vessel forma-
tion at the treated area. CAM incubated with all three
concentrations of HRL shows growth of new capillary ves-
sels at the treated area (Fig. 1a). After 72 h of incubation,
1 μg of HRL (Fig. 1a. d) exhibited minimal growth of ca-
pillaries around the sponge and is visually similar to that
of control CAM (Fig. 1a. b). Formations of new capillaries
were more prominent with 3 μg of HRL after 72 h and
this is evident with development of reddishness around
the sponge indicating increased vessel growth at the
treated area (Fig. 1a. f ). Spoke wheel pattern of allantoic
vessel growth is observed for this particular concentration.celerate vessel growth. a Images of CAM treated with 1, 3 and 5 μg
esents the images recorded at 0 and 72 hours of incubation. Increased
rved in CAM treated with 3 and 5 μg of HRL (f and h) than 1 μg treated
nd g represents 0 hour images of CAM for control , 1 and 3 and 5 μg of
ication and bar is 10 μM. Images are representative of 3 set of
the CAM recorded at 0, 24, 48 and 72 h of incubation were analysed
a) and vessel size (graph b) of the capillaries. CAM treated with 3 μg of
8 h of incubation. At 72 h of incubation both 3 and 5 μg of HRL shows
ion shows significant increase, the angiogenic potential of 3 μg of HRL is
. Experiments were performed in triplicate and data presented as mean +
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sels in and around sponge at 72 h but with lesser vessels
growth when compared to that of 3 μg (Fig. 1a. h).
From the above observation it can be inferred that,
both 3 and 5 μg concentration of HRL has the ability to
induce angiogenesis through new capillary formation at
72 h of incubation. In order to conform this and also to
arrive at the optimum working concentration for HRL
we measured the growth of the vessels in terms of its
length and size, from the images taken at 0, 24, 48 and
72 h of incubation with Image J and Angioquant
MATLAB software. This software is specially made for
quantifying angiogenesis using in vitro assays and has
been employed for CAM with some modifications using
Image J software [11, 13]. Of the three different concentra-
tions, used 3 μg of HRL demonstrates a significant in-
crease in the vessel length (Fig. 1b. b) and size (Fig. 1b. b)
at 48 h of incubation which is 1.99 fo1d greater than that
of control (#p = 0.001, *p = <0.001). At 72 h of incubation
both 3 and 5 μg of HRL induces a significant increase in
the vessel length and size (*p = <0.001) and of these two,
3 μg of leptin shows 2.1 fold increases in vessel growthFig. 2 Human recombinant leptin able initiate sprouting of new vessels fro
and 5 μg of HRL and control with 1X PBS for 72 h (Figures b, d, f, h are th
with 3 and 5 μg of HRL (e, f, g and h) shows the presences of branches an
blood vessel formation by sprouting and CAM treated with 1 μg of HRL (c
of beginning of sprouting of blood vessels when compared to control (a a
branches and sub branches at the treated area. Figure represents the imag
magnification of bar is 20 μM and are representative of 3 set of experimen
the main vesselwhich is higher than that of 5 μg that showed which has
only 1.8 fold increase. HRL of 1 μg also shows angiogenic
potential with increase in the vessel growth up to 1.5 fold,
the value is not significant when compared to control that
has 1.2 fold increase in the vessel growth from 0 to 72 h
of incubation. Thus it is obvious that HRL can induce new
vessel formation at the treated area in a dose dependent
manner with 3 μg concentration having maximum angio-
genic response.
Human recombinant leptin initiate growth of vessels by
means of sprouting – visualising the morphology of
blood vessels on CAM vascular bed
We analysed the morphology of blood vessels in order
to confirm the sprouting angiogenic ability of HRL at
the treated area. Images of the CAMs were recorded im-
mediately after 72 h of incubation using microscope. It
was found that HRL is able to induce growth of new
blood vessels from the existing one (Fig. 2). CAM incu-
bated with 3 μg of HRL shows more number of sprouting
vessels along with branches and sub branches at the
treated area (Fig. 2e). An enlarged view of the samem existing one. Light microscopic images of CAM treated with 1, 3
e enlarged version of a, c, e, g respectively). Images of CAM treated
d sub branches from the main blood vessels as an indication of new
and d) shows the presence of bulging like structures as an indication
nd b). Among 3 and 5 μg of HRL 3 μg shows the presences of more
es recorded at 72 h of incubation using light microscope at 20X
ts. Arrow indicates the presence of branches and sub branches from
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the main vessel and sub branches from the newly formed
vessels, a feature directly suggesting the fact that HRL of
this particular concentration and time of incubation exerts
its maximum angiogenic activity (Fig. 2f). CAM treated
with 5 μg of HRL also shows the presence of sprouting of
vessels from the main one with appearances of branches
and sub branches (Fig. 2g and h), but its potential to in-
duce new vessel formation at the treated area is compara-
tively lesser than that of 3 μg HRL. HRL of 1 μg also
shows the presence of sprouting structures from the main
vessel, but is not remarkably strong when compared to
other concentrations (Fig. 2c). An enlarged view of the
treated area for the same shows roughness throughout the
outer surface of the main blood vessel along with bulging
appearance suggestive of its potential to initiate sprouting
of new blood vessels at the treated area. Control CAM
doesn’t show any such sprout formation from the existing
vessels (Fig. 2a) and the enlarged view of the same indi-
cates stable blood vessel without any rough appearance or
bud like structures from that of main one (Fig. 2b). Thus,
HRL is able to induce sprouting of new vessels from the
existing one with maximum sprouting efficacy at 3 μg
concentration.Fig. 3 Human recombinant leptin induces morphological changes in favo
images of CAM treated with 1, 3 and 5 μg of HRL and control with 1X PB
(ae) epithelial layers with sub epithelial capillary network (SEC), CAM treat
allantoic epithelial layer along with small vessels at the stroma region. CA
large vessels at the surrounding of large one with increased tissue thickn
comparatively lesser number of small vessels around the large one than C
wound or inflammation. Representative sections are 7 μM in thickness an
lbv for large blood vessel and sbv for small blood vessel)Human recombinant leptin induces morphological
changes leading to neo vascularization – histological
observation of the CAM vasculature
To conform the angiogenic potential of HRL, we also
analysed the changes in the cellular morphology of the
CAM vasculature from cross sections of the treated area
stained with haematoxylin and eosin. Changes in the
morphology of the CAM vasculature has been changed
observed for all three concentrations of HRL and is indi-
cative of the positive angiogenic response due to HRL
(Fig. 3). CAM incubated with 1 μg of HRL (Fig. 3b) shows
irregular appearance of thin stratum (which contains both
chorionic (ce) and allantoic (ae) epithelial layers) with the
presences of few blood vessels at the primary stratum.
CAM treated with 3 μg of HRL (Fig. 3c) shows vessels en-
larged in size with remarkable irregular growth pattern at
thin stratum. Morphology of ECs are altered those ECs
which are present at the capillary plexus/blood sinus area
(which lies in between the primary and thin stratum)
shows sprouting appearance typical for angiogenesis.
Thickness of the primary stratum is also increased prob-
ably due to cellular accumulation at the sub epithelial
capillary network (SEC). Presences of a number of small
blood vessels around the main vessels is suggestive of theur of angiogenesis. Haematoxylin and eosin stained histological
S for 72 h. Control CAM (a) shows thin chorionic (ce) and allantoic
ed with 1 μg of HRL (b) shows comparatively thicker chorionic and
M treated with 3 μg of HRL (c) shows the presences of numerous
ess at the primary stratum. CAM treated with 5 μg of HRL (d)
AM treated with 3 μg of HRL. Gelatin sponges has not caused
d were recorded at 10X magnification and bar is 50 μM. (v for vein,
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sels or by inducing the sprouting from the main one.
CAM treated with 5 μg of HRL (Fig. 3d) also shows ir-
regular appearances at thin stratum due to increase in the
number of blood vessels and diminished accumulation of
cells were observed beneath SEC. Very few small vessels
were found around the large one as an indication of min-
imal sprouting which is lesser than that observed with
3 μg. Control CAM (Fig. 3a) shows a few scattered blood
vessels at primary stratum with uniform growth at the
thin stratum due to growth of less number of blood ves-
sels at this area. These observations demonstrates that
HRL is able to induce formation of new vessel growth by
inducing positive morphological changes at the cellular
level in favour of angiogenesis. Leptin of 3 μg concentra-
tion is capable of eliciting promising cellular response that
could lead to more angiogenic growth.
Human recombinant leptin increases the size of tissue by
means of inducing new vessel growth. Quantitative
measurement of the angiogenic potential of human
recombinant leptin by morphometric measurement of
CAM tissue thickness (DCAM)
The ability of 1, 3 and 5 μg of HRL to induce new ves-
sels growth was further confirmed by measuring the size
of the tissue from the from haematoxylin and eosin
stained paraffin embedded vertical cross sections and is
plotted as average tissue thickness (Fig. 4). Formation of
new blood vessels or enlargement or growth of the exist-
ing blood vessels will cause an increase in the thickness
of the CAM at the stroma and will push both theFig. 4 Human recombinant leptin increases the size of tissue by
means of inducing new vessel growth. Total thickness of the tissue
at the treated area with 1, 3 and 5 μg of HRL was measured from
haematoxylin and eosin stained vertical cross section after 72 h.
Control CAM was treated with 1X PBS. The distance between chorionic
and allantoic epithelial layers was calculated morphometrically in μM.
CAM treated with 3 μg of HRL shows significantly increased tissue
thickness than other two concentrations. Material shrinkage is estimated
to be ~25 % relative to the fresh material in all cases. Experiments
were performed in triplicate and data presented as mean + SEM,
(*p = <0.001versus control)chorionic and allantoic epithelial layer a part. In the
present study we calculated the distance between these
two layers (thin stratum) morphometrically in μM after
72 h of incubation. It is found that thickness of the CAM
is considerably increased significantly for 3 μg of HRL
(*p = <0.001) when compared to other two studied con-
centrations suggestive of its ability of to induce angiogen-
esis under this concentration. In paraffin-embedded
tissues, material shrinkage is estimated to be ~25 % rela-
tive to the fresh material and since all tissues were pre-
pared similarly, tissue shrinkage is assumed to be same for
all CAM zones. Thus, shrinkage corrections are not ne-
cessary while comparing tissue thickness [26].
Angiogenic potential of human recombinant leptin
depends on the activation of major angiogenic growth
factors - molecular profiling of VEGF 165, VEGF 121,
bFGF2, MMP2 and MMP9
The expression of primary angiogenic growth factors
such as VEGF, bFGF2, MMP2 and MMP9 during leptin
induced angiogenesis is analysed by measuring the vari-
ation in the mRNA level. In our study it is observed that
mRNA level expression of these specified angiogenic
growth factors increased when treated with HRL (Fig. 5).
The intensity of the bands were measured as relative OD
and given in Fig. 5b. There was a consistent increase in
the expression pattern for 3 μg HRL which is signifi-
cantly higher (*p = <0.001) than that of other two con-
centrations. It was also observed that for 5 μg of HRL
the relative mRNA level of VEGF165 and MMP2 in-
creased significantly (*p = <0.001) owing to the involve-
ment of these two main angiogenic growth factors on
HRL induced angiogenesis. The gene profiling data indi-
cates that the angiogenic ability of HRL mainly depends
on the activation VEGF165 and MMP2 since the expres-
sion value have increased significantly when treated with
3 and 5 μg of HRL. Thus, HRL at 3 μg concentration is
able to induce maximum angiogenic growth by increas-
ing the gene expression of VEGF121, bFGF2, MMP9
along with VGEF165 and MMP2.
Human recombinant leptin accelerates the gelatinase
activity of MMP2
The potential of HRL to induce neo vascularization was
measured intern by its ability to accelerate gelatinase ac-
tivity of MMP2 to degrade ECM in order to favour ECs
proliferation and migration. Figure 6a indicates that the
gelatinase activity of MMP2 is increased indicating ECs
proliferation and activation when treated with HRL. The
intensity value measured in terms of OD and the graph
plotted (Fig. 6b) shows that the gelatinase activity of
MMP2 is increased significantly (*p = <0.001) when
treated with 3 and 5 μg of HRL. The gelatin zymogram
analysis of MMP2 activity demonstrates that HRL has
Fig. 5 Human recombinant leptin enhances the mRNA level expression of VEGF165, VEGF121, bFGF2, MMP2 and MMP9. Images of Reverse
Transcriptase- PCR products of (a) VEGF165 (b) VEGF121 (c) bFGF2 (d) MMP2 and (e) MMP9 from CAM after treated with 1, 3 and 5 μg of HRL
and control with 1X PBS for 72 h. GAPDH was used as internal loading control. The transcripts were confirmed by 100bp DNA ladder. Graph
represents the OD value ratio of mRNA transcripts after normalizing with GADPH OD value of the same. The OD value was measured using Image
J software. The relative level expression of specified genes were increased significantly for 3 μg of HRL and under 5 μg of HRL the relative expression
of VEGF 165 and MMP2 increased significantly after 72 h of incubation.. Each value is the mean ± SEM, *p= <0.001 versus control, n = 3.
Experiments were performed in triplicate and data presented as mean + SEM. (Lane 1 - control, lane 2 – 1 μg HRL, lane 3 – 3 μg HRL and
lane 4- 5 μg HRL)
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of increasing the degradation of ECM. This data also in-
dicates that irrespective of the concentration, HRL isable to accelerate the gelatinase activity of MMP2 which
in turn signifies that MMP2 plays a major role in HRL
induced angiogenesis.
Fig. 6 Human recombinant leptin enhances the gelatinase activity
of MMP2. a Image represents the gelatin zymography of MMP2
activity from CAM after treated with 1, 3 and 5 μg of HRL and
control with 1X PBS for 72 h. The image shows that the gelatinase
activity was increased under 3 and 5 μg of HRL which is visible as
white band against black background. Image is the result of 3 set
of experiments. b MMP2 gelatinase activity was measured as OD
value using Image J software. Percentage of MMP2 gelatinase
activity increased significantly under 3 and 5 μg of HRL with higher
percentage under 3 μg of HRL. Each value is the mean ± SEM,
*p = <0.001 versus control, n = 3. (Lane 1- protein weight marker,
Lane 2 - control, lane 3–1 μg HRL, lane 4–3 μg HRL and lane
5–5 μg HRL)
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endothelial cells
From our data it is clear that the angiogenic potential of
HRL is maximum for 3 μg concentration enabling the
formation of new blood vessels at the treated area. Acti-
vation of ECs is considered as one of the major step in
angiogenic cascades especially during sprouting angio-
genesis [27]. The result obtained from the study confirm
the potential of HRL to activate ECs by identifying the
presence of CD34 (activated endothelial cell marker) ex-
pression on ECs. The result indicates that the CD34 ex-
pression is observed at capillary plexus or blood sinus
area in which ECs were pooled out along with angioblast
cells (Fig. 7b) and the pattern of staining resembles more
like coiled structures with elongated protrusions suggest-
ive of the sprouting of ECs under HRL (Fig. 7d). Also
the ECs present at the luminal side of the vessels shows
higher staining for CD34 than those present in the con-
trol (Fig. 7a). Presence of these elongated ECs is suggest-
ive of its enhanced proliferative capacity when treated
with HRL which in turn lead to the formation of capillary
like structure during the process of angiogenesis especially
when sprouting angiogenesis occurs (Fig. 7c and e). In
control, those ECs which were present at the lumen of the
main vessel shows CD34 expression and no staining wasobserved at the blood sinus area (Fig. 7a). Thus it can be
concluded that HRL has the ability to enhance EC activa-
tion which in turn can favour these cells to participate
actively in angiogenesis.
Angiogenic potential of human recombinant leptin
mainly depends on the activation of VEGF A and MMP2 –
protein expression
Molecular profiling of angiogenic factors after treatment
with HRL indicated that angiogenic potential of leptin
mainly depends on the functional activation of VEGF A
(VEGF 165) and MMP2. Hence we attempted to under-
stand the same by scoring the protein level expression of
VEGF A and MMP2 using immunohistochemical method.
Results show that with 3 μg concentration of HRL the ex-
pression of VEGF A protein (Fig. 8b) is higher at the
lumen of main vessels as well as at the surrounding small
ones as an indicating enhanced ECs activation while con-
trol shows the expression only at the luminal surface of
the main vessel (Fig. 8a). Expression of MMP2 protein
after HRL treatment seems to be more concentrated at
the vessel surface particularly at the lumen and also at the
thin epithelial layer which contains peptidoglycan extra
cellular matrix (Fig. 8d) and this is higher than that of
control (Fig. 8c). Presence of increased level of MMP2
protein at the lumen of the vessel is suggestive of the ac-
tive breakdown of extra cellular matrix in favour of ECs
migration and proliferation, support the occurrence of
sprouting angiogenesis after HRL treatment. Thus the ex-
pression pattern illustrates that HRL able can activate the
pool of ECs in such a way that these cells can actively par-
ticipate in the angiogenic cascade process. The results also
demonstrates that 3 μg of HRL is capable of inducing neo-
vascularization by increasing the degradation ECM which
in turn allows the micro vascular endothelial cells to mi-
grate, proliferate and differentiate. Presence of VEGF A at
the endothelium also indicates that 3 μg of HRL could
favour endothelial cell activation followed by sprouting,
initiating new blood vessel formation.
Discussion
Angiogenesis is defined as the formation of new blood
vessels from existing ones which plays an important role
in many physiological and pathological events [28]. Lep-
tin, the Ob gene product is known to exert its biological
activity through binding with it receptors termed Ob-R
identified in hypothalamus and also in peripheral vascu-
lar tissue such as ECs [1, 29]. Reports from various
in vivo analyses have suggested both angiogenic and anti
angiogenic property of leptin [3, 10]. But no reports have
yielded conclusion results. Reports have also suggested that
this dual function of leptin depends on multiple factors
such as dose, time of incubation, mode of administration
and to certain extent the type of species [3, 4, 8–10, 30].
Fig. 7 Human recombinant leptin activate endothelial cells. Images of CAM stained for CD34 under 3 μg leptin for 72 h. Control CAM treated
with 1X PBS for 72 h. Control (a) shows the expression of CD34 protein at the lumen of the blood vessel and CAM treated with 3 μg leptin
shows the expression at the capillary plexus or blood sinus area as coiled structure where endothelial cells pooled out (b, d) and also at those
endothelial cell which is present at the lumen of the blood vessel (c, e). Images were recorded using light microscope. Arrow indicates the
presence of CD34 protein, magnification 40X and bar is 50 μM
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HRL using in vivo CAM assay. The main advantage of
the assay is that it can be used as a rapid method of de-
termining the angiogenic responses because it is consid-
ered as an intermediate step between a single model
(cell culture) and a more complex system (mammalian
model). The other important advantage is that CAM can
be used to score the tissue responses towards the angio-
genic activity of bio materials accurately and are similar
to that of mammalian model responses [31] and also
helps in the maintenances of the test materials at the site
of administration. To overcome this technical problem
we used gelatin sponges for the delivery of the chemical
which can held and adhere firmly to the CAM surface
with no or less inflammatory reactions [13, 32].
In the present work we found that in ovo administra-
tion of HRL is able to induce neovascularization at the
treated area in a dose dependent manner. Among those
analysed concentration (1, 3 and 5 μg) only 3 μg of HRL
shows significant angiogenic response as observed the
increase in vessel growth at an early incubation period
of 48 h. The results are in accordance with the earlier re-
search report where the effect was prominent even at
24 h of incubation [5]. But this shorter time period of in-
cubation on CAM is considered as vasodilation period
rather than compound effect [13]. Hence in the present
study we performed the experiments for 72 h to analysethe angiogenic potential of HRL because at this time
point newly formed vessels will become stabilized. Inter-
estingly we found that at 72 h of incubation both 3 and
5 μg of HRL shows significant angiogenic effect indicating
that the angiogenic potential of HRL not only depends on
the concentration but also on the duration of incubation.
Microscopic analysis of the growth pattern of the vessels
implicates that 3 μg of leptin is able to induce more
sprouting of new vessels from the existing one when com-
pared to 5 μg concentration. Thus, HRL has the potential
to induce neovascularization in a dose dependent manner
and that 3 μg concentration could be more appropriate
resulting in earlier and stable angiogenesis.
Placing any foreign material onto CAM can develop
inflammatory reaction which can cause secondary vaso-
proliferative response leading to false positive conclusion
[13]. To avoid this issue we have performed a thorough
histological evaluation after adding HRL. Changes in the
histological structure and altered cellular morphology of
the treated area together indicated that HRL is able to
initiate new blood vessel formation without local inflam-
mation. HRL of 3 μg shows comparatively higher angio-
genic responses by accelerating the formation of new
vessel through sprouting from the major one. Also the
angiogenic or antiangiogenic effect of compound can be
effectively analysed by measuring the thickness of the
CAM at the treated area as formation and growth of the
Fig. 8 Human recombinant leptin induces the expression of VEGF165 and MMP2. Immunohistochemical images of CAM for VEGF165 and MMP2
after treated with 3 μg of HRL and control with 1X PBS for 72 h. CAM treated with 3 μg of HRL shows more expression of VEGF A at the lumen
of the blood vessels (fig b) and MMP2 at the stroma (fig d) than control (fig a and c). Images are representative of 3 set of experiments and were
recorded by light and BX51 Olympus fluorescence microscopes. Arrow indicates the presence of protein, magnification is 60X and bar 50 μM
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ness at the stroma region. Any changes related to the
growth at the stroma will push chorion and allantoic
epithelium a part [15]. In our study we found that 3 μg
of HRL is able to exert maximum angiogenic response at
the stroma region very near to chorionic epithelium ra-
ther than mesodermal layer by means of forming capil-
lary like tubes and structures leading to increased tissue
thickness.
Results from rat corneal assay as also from various
in vitro analyses showed that angiogenic effect of leptin
is mediated by VEGF [33] and is supported by matrix re-
modelling [34]. Molecular profiling of VEGF and its iso-
forms such as VEGF165 and VEGF121 indicates that
HRL induced angiogenesis mainly depends on the ex-
pression of VEGF165 rather than VEGF121. Increased
mRNA level of MMPs especially MMP2 confirmed the
major role of MMP2 in matrix remodelling during HRL
induced angiogenesis and is in agreement with the earl-
ier report [29, 34, 35]. Various reports have suggested
that the physiological functions of leptin get initiated
once it binds to its receptor Ob-R present in various cel-
lular systems. During angiogenesis leptin is shown to
exert its activity by binding with Ob-R receptor present
on ECs followed by up regulation of the downstreamsignalling [29]. Here also it is possible that the angio-
genic response of HRL on CAM is mediated by the
receptor Ob-R considering the fact that human and
chicken leptin receptor has 62 % of homology and the
structural domains of the receptor are highly conserved
in both [36]. The present data suggests that 3 μg of HRL
has more angiogenic potential by inducing the increased
mRNA level expression of VEGF165, VEGF121, bFGF2,
MMP2 and MMP9 and also the protein level expression
of VEGF165 and MMP2. Thus of HRL could up regulate
the expression of VEGF165 and MMP2 to induce neo-
vascularization resulting in the observed sprouting at the
area of treatment.
Activation of EC is considered as one of the most im-
portant and preliminary step in the cascade of angiogen-
esis [28]. In vitro analysis suggested that leptin could
initiate the activation of ECs to form tube like structures
while inducing angiogenesis [29]. In this work we also
analysed the potential effect of HRL on the activation of
ECs by studying the immuno localization of CD34 ex-
pression on CAM ECs. Presence of more activated ECs
at the blood sinus region along with coiled like struc-
tures formation of ECs at the sinus area together highly
support the ability of HRL to activate ECs during angio-
genesis. Presences of elongated ECs at the lumen of the
Manjunathan and Ragunathan Biological Research  (2015) 48:29 Page 12 of 13vessel also indicates that 3 μg of HRL could be the
optimum concentration that can initiate the formation
of new capillary like structures which is remarkable at
the first phase of sprouting angiogenic process.
Conclusion
The present work demonstrates that HRL has the poten-
tial to induce neovascularization by means of sprouting
at the treated area. Expression of CD34 on activated ECs
indicates that HRL can initiate the activation ECs and
could favour the formation of tube like structure from
the pool of ECs. Increased tissue thickness and altered
cellular morphology of CAM with HRL treatment sup-
ports dose dependent angiogenic ability of HRL. It was
also observed that HRL induced angiogenesis mainly de-
pends on the activation of VEGF165 and MMP2. Direct
visualization and growth of newly formed vessels at the
treated area demonstrates that the angiogenic ability es-
pecially sprouting effect of HRL depends on the concen-
tration and time of incubation. It is found that 3 μg of
HRL exhibits significant angiogenic response at 72 h of
incubation. Altogether our findings suggest that HRL
could be a useful angiogenic therapeutic molecule and
can be more effectively used in the future especially for
the treatment of ischemic disorders and wound healing
which requires new vessel formation.
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